Role of Epidermal Growth Factor (EGF) in Development of Necrotizing Enterocolitis

Completed

Conditions studied: Necrotizing Enterocolitis, Premature Birth

In brief

Necrotizing enterocolitis (NEC) is a serious gastrointestinal disorder that primarily affects preterm infants. About 10% of babies less than 32 weeks gestation at birth will develop it. Overall, 30% of babies who develop NEC will die from it, with many others developing long term gastrointestinal problems. The most important factor in its development is a premature intestinal tract. Epidermal growth factor (EGF) is an important growth factor in the development and maintenance of the gastrointestinal tract. This study will look for a relationship between EGF levels in premature babies and the development of NEC.

Key facts

Study ID

NCT00059449

Run by

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

People needed

372

Last updated by the study team

2010-01-13

Who can join

Age: any, up to 0. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Gestational Age greater than 23 weeks at birth
• Birth weight greater than 500 grams
• Age less than 72 hours of life

Where it is running

• Good Samaritan Hospital — Cincinnati, Ohio, United States
• Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States
• University Hospital — Cincinnati, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.